Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes - Scientific Reports
Source : https://www.nature.com/articles/s41598-022-12973-0
Heart failure with reduced ejection fraction (HFrEF) is increasingly treated with medications for type 2 diabetes mellitus (T2DM). Whether metabolic derangements in HFrEF and T2DM are associated with differential outcomes...
Conclusion/Relevance: We identified metabolites of BCAA, urea cycle and fatty acid metabolism as biomarkers of HFrEF outcomes, with observed differences in HFrEF patients with T2DM. Such biomarkers might enable future diagnostic or therapeutic interventions in individuals with HFrEF and T2DM.
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-022-01041-7
Purpose of Review The burden of obesity worldwide is high and projected to rise. Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk factors; hence, utilizing effective long-term...
Summary: GLP-1RAs have robust weight loss benefits and are expected to have a critical role in the management of obesity in the coming years. Upcoming studies will evaluate the durability of weight loss achieved with GLP-1RAs and the impact on cardiovascular outcomes.
Disparity in association of obesity measures with ankle and brachial systolic blood pressures in Europeans and South Asians - Scientific Reports
Source : https://www.nature.com/articles/s41598-022-13372-1
Obesity causes increases in brachial systolic-blood-pressures (SBP), risks of type 2 diabetes (T2DM) and cardiovascular diseases (CVD). Brachial and ankle SBPs have differential relationship with T2DM and CVD. Our objective...
Relevance: Brachial and ankle SBPs have differential relationship with T2DM and CVD. Our objective was to study the relationship of obesity measures with brachial and ankle SBPs.
Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses
Source : https://elifesciences.org/articles/73138
Patients with Type 2 diabetes show patterns of neurodegeneration consistent with accelerated brain aging, including impaired cognition and loss of brain volume, which are more severe in those with increased...
Conclusions: The neurocognitive impact of T2DM suggests marked acceleration of normal brain aging. T2DM gray matter atrophy occurred approximately 26% ± 14% faster than seen with normal aging; disease duration was associated with increased neurodegeneration. Mechanistically, our results suggest a neurometabolic component to brain aging....
Semaglutide Initiation in a Type 2 Diabetes Mellitus, Post-Liver Transplant Patient - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35610766/
Objective To describe the process of initiation of semaglutide for complex management of type 2 diabetes mellitus (T2DM) in a patient after liver transplantation. Setting Family medicine clinic. Practice Description...
Conclusion: Semaglutide, in addition to basal-bolus insulin therapy, allowed for overall improved glycemic control; however, further studies are needed to evaluate efficacy because of the complexity of diabetes management in this patient population. Throughout the course of treatment of patients with T2DM and organ transplantation, dual...